医学
药品
重症监护医学
药物发现
药物开发
周转时间
药理学
药品审批
肿瘤科
生物信息学
计算机科学
生物
操作系统
作者
Carlo Toniatti,Philip S. Jones,Hilary Graham,Bruno Pagliara,Giulio Draetta
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2014-04-01
卷期号:4 (4): 397-404
被引量:50
标识
DOI:10.1158/2159-8290.cd-13-0452
摘要
We have made remarkable progress in our understanding of the pathophysiology of cancer. This improved understanding has resulted in increasingly effective targeted therapies that are better tolerated than conventional cytotoxic agents and even curative in some patients. Unfortunately, the success rate of drug approval has been limited, and therapeutic improvements have been marginal, with too few exceptions. In this article, we review the current approach to oncology drug discovery and development, identify areas in need of improvement, and propose strategies to improve patient outcomes. We also suggest future directions that may improve the quality of preclinical and early clinical drug evaluation, which could lead to higher approval rates of anticancer drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI